Clinical Trials Directory

Trials / Unknown

UnknownNCT03059875

Place of Comprehensive Geriatric Assessment in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter)

Place of Comprehensive Geriatric Assessment (CGA) in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter): Comparison Between CGA Before Surgery (Strategy A) vs. After Surgery (Strategy B)

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
79 (actual)
Sponsor
Poitiers University Hospital · Academic / Other
Sex
Female
Age
75 Years
Healthy volunteers
Not accepted

Summary

The risk of diagnosis of cancer increases with age, especially breast cancer in elderly women. Elderly population is heterogeneous, regarding physiological reserves, comorbidities, disability and geriatric conditions. Comprehensive geriatric assessment (CGA) is a multidimensional approach to determine geriatric profile, in helping the therapeutic strategy. In-patients with diagnosis of cancer are screened with the FOG (oncology geriatric filter), to identify vulnerable subjects who may benefit from CGA. This scale of ten questions includes geriatric domains such as functional status, nutrition, mood, cognitive abilities and comorbidities. In elderly patients with breast cancer considered as fit (FOG=0), CGA is not necessary before adjuvant treatment. In vulnerable patients (FOG ≤ 1 and \< 3), CGA is held in routine to discuss the adjuvant therapy feasibility. Patients with FOG ≥ 4 underwent CGA if palliative care is considered. Patients in the intermediate group (FOG 1-3) are randomized to determine time of CGA, before or after surgery. The aims of this study are to assess the outcomes regarding the time of CGA, in elderly female patients with breast cancer management, and to define the optimal place of CGA in care pathway.

Conditions

Interventions

TypeNameDescription
BEHAVIORALMedical consultation for a Standardized Geriatric Evaluation

Timeline

Start date
2014-01-30
Primary completion
2021-07-31
Completion
2025-07-31
First posted
2017-02-23
Last updated
2021-09-29

Locations

6 sites across 1 country: France

Source: ClinicalTrials.gov record NCT03059875. Inclusion in this directory is not an endorsement.